Agenus Earnings Reports

Agenus reported Q4 2024 revenue of $26.8 million but incurred a net loss of $46.8 million. The company continued its cost-cutting strategy, reducing its operational burn rate and monetizing non-core assets. Significant progress was made in its BOT/BAL program, with external clinical trials validating its potential. The company also ended the year with $40.4 million in cash and cash equivalents.

Agenus reported revenue of $25.1 million and a net loss of $67.2 million for Q3 2024. The company is focused on advancing BOT/BAL, strategic initiatives including asset monetization and operational efficiencies to strengthen its financial position.

Agenus reported revenue of $23.5 million for the second quarter of 2024 and a net loss of $54.8 million. The company's cash balance was $93.7 million at the end of the quarter. Agenus is focused on advancing its BOT/BAL program and is in discussions with potential partners.

Agenus announced a $100 million royalty financing agreement with Ligand to support BOT/BAL development and launch readiness. The company reported positive clinical results from Phase 1 and Phase 2 studies of BOT/BAL in metastatic relapsed/refractory colorectal cancer. Agenus successfully reduced its cash burn rate and regained compliance with Nasdaq listing.

Agenus reported a net loss of $64.5 million for Q3 2023, with revenue of $24.3 million. The company is focusing on the development of botensilimab and plans to submit a BLA to the FDA for MSS CRC in mid-2024. Agenus believes it is sufficiently funded through the end of 2024 with a cash, cash equivalent, and short-term investment balance of $106.3 million.

Agenus reported Q2 2023 results, highlighting the promising clinical activity of botensilimab, particularly in colorectal cancer, and the FDA's Fast Track designation for the botensilimab/balstilimab combination. The company is advancing its clinical pipeline and preparing for a regulatory submission for botensilimab/balstilimab in colorectal cancer. The company ended the quarter with $157.6 million in cash, cash equivalents and short-term investments, and raised $20.3 million through sales of common stock since the end of Q2 2023. Revenue for the quarter was $25.3 million, and the net loss was $73.4 million.

Agenus Inc. announced its financial results for the quarter ended March 31, 2023.

Agenus reported revenue of $28 million and a net loss of $74 million for the fourth quarter of 2022. The company ended the year with a cash, cash equivalent, and short-term investment balance of $193 million.

Agenus reported revenue of $22.8 million and a net loss of $56.7 million, or $0.19 per share, for the third quarter ended September 30, 2022. The company ended the quarter with $218.2 million in cash, cash equivalents, and short-term investments.

Agenus reported a revenue of $21 million for the second quarter ended June 30, 2022, representing an increase of $10 million from the same period in 2021. The net loss for the quarter was $49 million or $0.17 per share, compared to a net loss of $84 million or $0.37 per share for the quarter ended June 30, 2021.

Agenus reported a revenue of $26 million for the quarter ended March 31, 2022, an increase of $14 million compared to the same quarter in 2021. The net loss for the quarter was $51 million, with per share losses of $0.19. The company ended the quarter with $263 million in cash and short-term investments.

Agenus reported a net income of $177 million, or $0.76 per share basic and $0.72 per share diluted, and ended the quarter with $262 million in cash and short-term investments. The company also highlighted clinical responses achieved with AGEN1181, the launch of MiNK Therapeutics' IPO, and the launch of its adjuvant business, SaponiQx.

Agenus reported a net loss of $84 million, or $0.37 per share, for the second quarter of 2021. The company's cash balance was $74 million at the end of the quarter, compared to $100 million at the end of 2020. Subsequent to the quarter end, Agenus received $200 million related to their BMS partnership.

Agenus reported a net loss of $54 million, or $0.27 per share, for the quarter ended March 31, 2021. The company ended the quarter with a cash balance of $119 million. Revenue for the quarter was $12 million.

Agenus reported a net loss for the fourth quarter of 2020, and the initiation of their rolling BLA filing for balstilimab monotherapy.

Agenus reported a net loss of $52 million, or $0.28 per share, for the third quarter of 2020. The company's cash balance at the end of the quarter was $114 million.

Agenus reported a net loss of $48 million, or $0.28 per share, for the second quarter of 2020. The company's cash balance at the end of the quarter was $79 million. Agenus recognized revenue of $26.945 million for the quarter.